The bumpy road to evidence: Why many research findings are lost in translation

European Heart Journal

Volumn 34, Issue 43, 2013, Pages 3329-3335

  Lüscher, Thomas F ^a  

^a Zurich Heart House ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CELECOXIB; CILAZAPRIL; COENZYME A; CYCLOOXYGENASE 2 INHIBITOR; DALCETRAPIB; ENCAINIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; MORACIZINE; NICOTINIC ACID; PHOSPHODIESTERASE INHIBITOR; RAPAMYCIN; ROFECOXIB; SOTALOL; STREPTOMYCIN; TGN 1412; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ALDOSTERONE RELEASE; ANESTHESIA; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; B CELL LEUKEMIA; BIOMEDICINE; BLEEDING; BLOOD VESSEL INJURY; CAROTID ARTERY; CHRONIC LYMPHATIC LEUKEMIA; CITRUS FRUIT; CLINICAL TRIAL (TOPIC); CYTOKINE STORM; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART SURGERY; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMICS; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERPLASIA; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MEDICAL LITERATURE; MEDICAL RESEARCH; NATURAL SCIENCE; NONHUMAN; PEER REVIEW; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; RESUSCITATION; RHEUMATOID ARTHRITIS; SCURVY; SIDE EFFECT; STENT; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; VACCINATION;

ANIMALS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL MEDICINE; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; HUMANS; INVENTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCIENCE;

EID: 84890485374     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht396     Document Type: Article

References (80)

1. MatsonW. Grand Theories and Everyday Beliefs: Science, Philosophy, and Their Histories. Oxford: Oxford University Press; 2011. p65-74.
2. Lüscher TF. Vom Symbol zum Organ. In: Gedankenmedizin. Heidelberg: Springer; 2010. p37-60.
3. Braunwald E. The rise of cardiovascular medicine. Eur Heart J 2012;33:838-845.
4. Popper K. Conjectures and Refutations. The Growth of Scientific Knowledge. London: Routledge and Kegan Paul; 1974.
5. Lüscher TF. Good publishing practice. Eur Heart J 2012;33:557-561.
6. Popper KR. The logic of scientific discovery. London: Taylor and Francis; 2002.
7. Taleb NN. The Black Swan -The Impact of the Highly Improbable. London: Penguin Books; 2008.
8. Kuhn TS. The Structure of Scientific Revolution. Chicago: University of Chicago Press; 2012.
9. Anitschkow N. Experimental arteriosclerosis in animals. In: Cowdry EV, ed. Arteriosclerosis: A Survey of the Problem. New York: Macmillan; 1933.
10. Dawber TR. The Framingham Study. The Epidemiology of Atherosclerotic Disease. A Commonwealth Fund book. Cambridge, MA: Harvard University Press; 1980.
11. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344: 1383-1389.
12. Lüscher TF. In search of the right word: A statement of the HEART Group on scientific language. Eur Heart J 2013;34:7-9.
13. Lind J. Treatise on the Scurvy. In three parts. 3rd ed., enlarged and improved. Printed for S. Crowder, D. Wilson, and G. Nicholls, T. Cadwell, T. Becket and Co., London; 1772.
14. Mann T. The Magic Mountain. London: Pinguin; 1955.
15. Hill AB. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. Br Med J 1948;769-773.
16. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
17. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, Yang Z, Turina M, Grädel E, Weber E, Bühler FR. Difference between endotheliumdependent relaxations in arterial and in venous coronary bypass grafts. N Engl J Med 1988;319:462-467.
18. Förstermann U, SessaWC.Nitric oxide synthases: regulation and function. Eur Heart J 2012;33:829-837.
19. Mancini JGB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG,Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on reversing endothelial dysfunction) study. Circulation 1996;94:258-265.
20. Lüscher TF, Pieper M, Tendera M, Vrolix M, Rutsch W, van den Branden F, Gil R, Bischoff KO, Haude M, Fischer D, Meinertz T, Münzel T. A randomized placebocontrolled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009;30:1556-1558.
21. Lüscher TF. The codex of science: honesty, precision, and truth -And its violations. Eur Heart J 2013;34:1018-1023.
22. Powell JS, Clozel JP, Müller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
23. The MERCATORstudy group.Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992;86:100-110.
24. Berger PB, Holmes DR Jr, Ohman EM, O'Hanesian MA, Murphy JG, Schwartz RS, Serruys PW, Faxon DP. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). J Am Coll Cardiol 1996;27:1-7.
25. HünigT.The storm has cleared: lessons from theCD28superagonistTGN1412 trial. Nat Rev Immunol 2012;12:317-318.
26. Church DM, Goodstadt L, Hillier LW, Zody MC, Goldstein S, She X, Bult CJ, Agarwala R, Cherry JL, DiCuccio M, Hlavina W, Kapustin Y, Meric P, Maglott D, Birtle Z, Marques AC, Graves T, Zhou S, Teague B, Potamousis K, Churas C, Place M, Herschleb J, Runnheim R, Forrest D, Amos-Landgraf J, Schwartz DC, Cheng Z, Lindblad-Toh K, Eichler EE, Ponting CP, the Mouse Genome Sequencing Consortium. Lineage-specific biology revealed by a finished genome assembly of the mouse. PLoS Biol 2009;7:e1000112.
27. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.
28. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Lüscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka FT, Lincoff AM, Nissen SE, PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009;157:606-612.
29. Landmesser U, von Eckardstein A, Kastelein J, Deanfield J, Lüscher TF. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: A rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J 2012;33:1712-1715.
30. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
31. Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, Dorries C, Besler C, Lüscher TF, Ruschitzka F. Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2012;33:1615-1624.
32. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33:857-865.
33. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367: 2089-2099.
34. Besler C, Heinrich H, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, Eckardstein AV, Fogelman AM, Lüscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on ENOS-Activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-2708.
35. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
36. HPS 2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291.
37. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, Landmesser U. Altered activation of endothelial anti-And proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoproteinproteome remodeling.Circulation 2013;127:891-904.
38. Charakida M, Masi S, Lüscher TF, Kastelein JJP, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 2010;31:2854-2861.
39. Achenbach S, Raggi P. Imaging of coronary atherosclerosis by computed tomography. Eur Heart J 2010; 31:1442-1448.
40. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J 2010;3:2456-2469.
41. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, Akasaka T, Costa M, Guagliumi G, Grube E, Ozaki Y, Pinto F, Serruys PWJ. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010;31: 401-415.
42. Reiner Z, Catapano AL,DeBacker G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF,Wood D, The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-1818.
43. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Boehm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RM, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension. Eur Heart J 2013;34: 2159-2219.
44. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
45. Waldo AL,CammAJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12.
46. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, and the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
47. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Boehm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zeiher AM, The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787-1847.
48. Gardnera RS,O? zalp F, Murday AJ, Robb SD, McDonagh TA. N-Terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-1743.
49. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF, EARTH investigators. Long-Term effects of darusentan on leftventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347-354.
50. Packer M, on behalf of the ENABLE investigators. Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure. Results of the ENABLE 1 and 2 Trial Program. Presented at the American College of Cardiology 2002.
51. Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294:218-228.
52. Krimsky S. Science in the Private Interest. Lanham, MD: Bowman & Littlefield Publishers, Inc.; 2003. p28-33.
53. Lüscher TF, Gedankenmedizin F. In: Conflict of Interest oder Interesse am Konflikt? Heidelberg: Springer; 2010. p123-136.
54. Peltz G. Can 'humanized' mice improve drug development in the 21st century? Trends Pharmacol Sci 2013;34:255-260.
55. Fanelli D.Howmany scientists fabricate and falsify research?Asystematic reviewand meta-Analysis of survey data. PLoS One 2009;4:e5738.
56. Nallamothu BK, Lüscher TF. From impact to influence: measurement and the changing role of medical journals. Eur Heart J 2012;33:2892-2896.
57. Bagley CG. Six red flags for suspect work. Nature 2013;497:433-434.
58. Camici GG, Steffel J, Akhmedov A, Schaefer A, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Lüscher TF, Tanner FC. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation and vascular smoothmuscle activation: A potential treatment strategy for drug-eluting stents. Circulation 2006;114:1512-1521.
59. Lüscher TF, Gersh B, Brugada J, Landmesser U, Ruschitzka F, SerruysPW. The European Heart Journal goes global: the road ahead of the editorial team 2009-2011. Eur Heart J 2009;30:1-5.
60. Lüscher TF, Brugada J, Gersh BJ, Landmesser U, Serruys PW, Murphy S, Dedecke S, Rogers S, Ruschitzka F. Happy birthday European Heart Journal: in 30 years, from Cinderella to centre stage. Eur Heart J 2010;31:1945-1950.
61. FrancisDP, Mielewczik M, Zargaran D, Cole GD. Autologous bone marrow-derived stem cell therapy in heart disease: discrepancies and contradictions. Int J Cardiol; doi: 10.1016/j.ijcard.2013.04.152. Published online ahead of print 26 June 2013.
62. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Albenc-Gelos F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
63. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, Collins R, for the International Studies of Infarct Survival (ISIS) Collaborators. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000;355:434-442.
64. Heinze G, Jüni P. An overview of the objectives of and the approaches to propensity analysis. Eur Heart J 2011;32:1704-1708.
65. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-762.
66. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
67. Southworth MR, Rechman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-1274.
68. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS, QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-1063.
69. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000;342:145-153.
70. Head SJ, Kaul S, Bogers AJJC, Kappetein AP. Non-inferiority study design: lessons to be learned from cardiovascular trials. Eur Heart J 2012;33:1318-1324.
71. de Boer SPM, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E. Evaluating the 'all-comers' design: A comparison of participants in two 'all-comers' PCI trials with non-participants. Eur Heart J 2011;32:1854-1864.
72. Hordijk-Trion M, Lenzen MJ, Wijns W, de Jaegere PJ, Simoons ML, Scholte OP, Reimer WJM, Bertrand ME, Mercado N, Boersma E. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 2006;27: 671-678.
73. Vist GE, Bryant D, Somerville L, Birmingham T, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008; MR000009.
74. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KAA, Kristensen SD, Rao SV, VerheugtFWA, Widimsky P, ZeymerU, Collet JP. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011;32:1854-1864.
75. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, SerruysPW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012;33:2403-2418.
76. Lüscher, Gersh B, Hindricks G, Landmesser U, Nallamothu B, Ruschitzka F, WijnsW. The European Heart Journal on the move: can scientific publishing be further improved? Eur Heart J 2013;34:409-415.
77. Lüscher TF, Gersh B, Hendricks G, Landmesser U, Ruschitzka F, WijnsW. The best of the European Heart Journal: look back with pride. Eur Heart J 2012;33:1161-1171.
78. Lüscher TF, Simoons ML. The European Heart Journal launches Ethics Review Board (CardioPulse). Eur Heart J 2013;34:2107-2113.
79. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847-1857.
80. Lüscher TF, Landmesser U, Ruschitzka F. Standing firm -The European Heart Journal, scientific discoveries and the industry. Eur Heart J 2010;31:1157-1158.